UNSPSC 51373417: Brompheniramine/codeine/phenylpropanolamine

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE301. This VA Drug Class (RE301) classifies this compound as belonging to the group OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS.

UNSPSC 51373417 Brompheniramine/codeine/phenylpropanolamine is a Commodity code that, based on recent state and local solicitations, captures pharmaceutical products and medical supplies — specifically parenteral products, IV solutions, controlled substances, and opioid-reversal agents — procured by state health and correctional agencies and county public health departments. The Washington State Department of Corrections is soliciting parenteral nutrition solutions, intravenous products, and other controlled pharmaceuticals for delivery to eight correctional facilities across three regions, with a pre-bid conference scheduled for September 23, 2026 and quotes due October 7, 2026; the RFQ encourages participation from small, minority-owned, women-owned, and veteran-owned businesses and anticipates awarding up to three contractors per region under an initial term through June 30, 2030. State and local buyers under this code include correctional health systems and county public health authorities.

Recent activity appears concentrated in Washington state and Florida. The Washington State Department of Corrections issued RFQ RFQQK13020 for parenteral products and services, while Seminole County, Florida issued IFB 60459723LAS for naloxone and drug deactivation systems with quarterly deliveries. Contractors must meet state licensure, background clearance, and insurance requirements (including Commercial General Liability, Professional Liability, Business Automobile Liability, and Cyber Liability coverage); Washington's solicitation requires NCIC clearance for all employees and names the state as an additional insured. The code appears lightly active in recent state and local procurement, with these two opportunities spanning correctional health provisioning and community opioid-response programs.